Rezolute, Inc.

Healthcare · Biotechnology · United States

Last price 3.95 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 414.34M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquar...